The open prostate cancer journal最新文献

英文中文

新規PET検査の進歩 (特集前立腺がんのスクリーニングと診断) PET检查的新进展(专题前列腺癌的筛查和诊断)

The open prostate cancer journal

Pub Date : 2015-10-01 DOI: 10.1097/00003072-199911000-00037

上島修一, 加藤精二, 宋本尚俊

引用次数: 0

PVP : 効率的な蒸散のために (特集前立腺肥大症手術のコツとトラブルシューティング) PVP:为了高效的蒸腾(专题前列腺增生手术的诀窍和故障排除)

The open prostate cancer journal

Pub Date : 2015-10-01 DOI: 10.1007/978-0-387-30160-0_9469

黒松功

引用次数: 0

強度変調放射線治療(IMRT) (特集前立腺がんに対する放射線治療最前線) -- (放射線治療の新規技術による治療成績と適応拡大) 调强放疗(IMRT)(专题前列腺癌放疗前沿)——(基于放疗新技术的治疗成绩和适应症扩大)

The open prostate cancer journal

Pub Date : 2015-04-01 DOI: 10.1201/9781420034110.ch1

溝脇尚志

引用次数: 0

専門医試験に役立つ前立腺知識日本泌尿器科学会専門医資格試験2013年度解説 : 前立腺癌関連専门医试験に役立つ前立腺知识日本泌尿器科学会専门医资格试験2013年度解说 : 前立腺癌関连

The open prostate cancer journal

Pub Date : 2014-10-01 DOI: 10.5123/s2176-62232013000400011

伊藤一人

引用次数: 0

QOL,患者の満足度 (特集前立腺がんの手術) -- (ロボット支援手術について) QOL，患者满意度(专题前列腺癌手术)——(关于机器人辅助手术)

The open prostate cancer journal

Pub Date : 2014-04-01 DOI: 10.1007/978-3-540-29805-2_3691

海法康裕, 荒井陽一

引用次数: 0

Ganoderic Acid DM: An Alternative Agent for the Treatment of Advanced Prostate Cancer. 灵芝酸DM:一种治疗晚期前列腺癌的替代药物。

The open prostate cancer journal

Pub Date : 2010-01-01 DOI: 10.2174/1876822901003010078

Benjamin M Johnson, Bently P Doonan, Faisal F Radwan, Azizul Haque

Prostate cancer is the most commonly diagnosed cancer in men and accounts for significant morbidity and mortality in the western world. While traditional therapies are effective at clearing early stage cancer, they often fail to treat late stage metastatic disease. Thus, an effective therapy that targets prostate tumor growth and metastasis is desired for alleviating the disease and improving patient outcomes. Natural extracts have been the focus of recent investigation, particularly those with reduced cellular toxicity to healthy tissue. In this review, we discuss one potential candidate, ganoderic acid, an extract from the Ganoderma lucidum mushroom that has been tested in multiple cancer models. Interestingly, ganoderic acid DM (GA-DM) has shown toxicity to both androgen-dependent and independent prostate cancer cells with reduced osteoclastogenesis in late stage metastatic disease. This review will discuss the current knowledge on this GA-DM extract and the potential benefit in treating advanced prostate cancer. We will also provide an overview on the targeted delivery of GA-DM through nanoparticles that would reduce bystander toxicity and improve the drug's effectiveness. An improved understanding of this drug and its uses will advance the field of natural chemotherapeutics, particularly in treating advanced prostate cancer.

前列腺癌是男性中最常见的癌症，在西方世界发病率和死亡率都很高。虽然传统疗法在清除早期癌症方面是有效的，但它们往往不能治疗晚期转移性疾病。因此，需要一种针对前列腺肿瘤生长和转移的有效治疗方法来缓解疾病并改善患者预后。天然提取物一直是最近研究的重点，特别是那些对健康组织的细胞毒性降低的提取物。在这篇综述中，我们讨论了一种潜在的候选者，灵芝酸，一种从灵芝蘑菇中提取的提取物，已经在多种癌症模型中进行了测试。有趣的是，在晚期转移性疾病中，灵芝酸DM (GA-DM)已显示出对雄激素依赖性和独立型前列腺癌细胞的毒性，这些细胞的破骨细胞生成减少。这篇综述将讨论GA-DM提取物目前的知识和治疗晚期前列腺癌的潜在益处。我们还将概述通过纳米颗粒靶向递送GA-DM，这将减少旁观者毒性并提高药物的有效性。对这种药物及其用途的进一步了解将推动天然化疗领域的发展，特别是在治疗晚期前列腺癌方面。

{"title":"Ganoderic Acid DM: An Alternative Agent for the Treatment of Advanced Prostate Cancer.","authors":"Benjamin M Johnson, Bently P Doonan, Faisal F Radwan, Azizul Haque","doi":"10.2174/1876822901003010078","DOIUrl":"https://doi.org/10.2174/1876822901003010078","url":null,"abstract":"Prostate cancer is the most commonly diagnosed cancer in men and accounts for significant morbidity and mortality in the western world. While traditional therapies are effective at clearing early stage cancer, they often fail to treat late stage metastatic disease. Thus, an effective therapy that targets prostate tumor growth and metastasis is desired for alleviating the disease and improving patient outcomes. Natural extracts have been the focus of recent investigation, particularly those with reduced cellular toxicity to healthy tissue. In this review, we discuss one potential candidate, ganoderic acid, an extract from the Ganoderma lucidum mushroom that has been tested in multiple cancer models. Interestingly, ganoderic acid DM (GA-DM) has shown toxicity to both androgen-dependent and independent prostate cancer cells with reduced osteoclastogenesis in late stage metastatic disease. This review will discuss the current knowledge on this GA-DM extract and the potential benefit in treating advanced prostate cancer. We will also provide an overview on the targeted delivery of GA-DM through nanoparticles that would reduce bystander toxicity and improve the drug's effectiveness. An improved understanding of this drug and its uses will advance the field of natural chemotherapeutics, particularly in treating advanced prostate cancer.","PeriodicalId":22947,"journal":{"name":"The open prostate cancer journal","volume":"3 ","pages":"78-85"},"PeriodicalIF":0.0,"publicationDate":"2010-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4002166/pdf/nihms434200.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32309713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 23

Human Cell Surface Receptors as Molecular Imaging Candidates for Metastatic Prostate Cancer. 人细胞表面受体作为转移性前列腺癌的分子成像候选者。

The open prostate cancer journal

Pub Date : 2009-01-01 DOI: 10.2174/1876822900902010059

Isis C Sroka, Gerald D Pond, Raymond B Nagle, Frank Porreca, Tamara King, Gary Pestano, Bernard W Futscher, Jaime M Gard, Janice Riley, Anne E Cress

Existing clinical imaging procedures lack sensitivity and specificity in detecting early prostate cancer bone metastatic lesions. In this study, we developed a highly reproducible bone metastasis xenograft model and identified possible molecular imaging candidates for detecting early bone metastatic lesions. Bone trophic human prostate cells (PC-3B1) were isolated and characterized for their ability to reach bone after intracardiac injection into SCID mice. The appearances of skeletal metastases were evaluated using digital radiographic imaging and confirmed by necropsy and histology. The PC-3B1 cells retain a bone homing phenotype after long term propagation in tissue culture and exhibit progressive bone lesions within 3 weeks following intracardiac injection. Comparative transcription signatures of PC-3 and PC-3B1 cells were determined using a cancer specific microarray and confirmed by RT-PCR analysis. The analysis identified increased expression of four cell surface molecules in PC-3B1 cells that may be suitable as molecular imaging candidates to detect bone micro metastases.

现有的临床影像学方法在检测早期前列腺癌骨转移病变方面缺乏敏感性和特异性。在这项研究中，我们建立了一个高度可重复的骨转移异种移植模型，并确定了可能用于检测早期骨转移病变的分子成像候选物。骨营养性人前列腺细胞(PC-3B1)被分离出来，并在SCID小鼠心内注射后被鉴定为能够到达骨。骨骼转移灶的表现采用数字放射成像评估，并经尸检和组织学证实。PC-3B1细胞在组织培养中长期繁殖后仍保持骨归巢表型，并在心脏内注射后3周内表现出进行性骨病变。使用肿瘤特异性芯片检测PC-3和PC-3B1细胞的比较转录特征，并通过RT-PCR分析证实。分析发现PC-3B1细胞中四个细胞表面分子的表达增加，可能适合作为检测骨微转移的分子成像候选物。

{"title":"Human Cell Surface Receptors as Molecular Imaging Candidates for Metastatic Prostate Cancer.","authors":"Isis C Sroka, Gerald D Pond, Raymond B Nagle, Frank Porreca, Tamara King, Gary Pestano, Bernard W Futscher, Jaime M Gard, Janice Riley, Anne E Cress","doi":"10.2174/1876822900902010059","DOIUrl":"https://doi.org/10.2174/1876822900902010059","url":null,"abstract":"<p><p>Existing clinical imaging procedures lack sensitivity and specificity in detecting early prostate cancer bone metastatic lesions. In this study, we developed a highly reproducible bone metastasis xenograft model and identified possible molecular imaging candidates for detecting early bone metastatic lesions. Bone trophic human prostate cells (PC-3B1) were isolated and characterized for their ability to reach bone after intracardiac injection into SCID mice. The appearances of skeletal metastases were evaluated using digital radiographic imaging and confirmed by necropsy and histology. The PC-3B1 cells retain a bone homing phenotype after long term propagation in tissue culture and exhibit progressive bone lesions within 3 weeks following intracardiac injection. Comparative transcription signatures of PC-3 and PC-3B1 cells were determined using a cancer specific microarray and confirmed by RT-PCR analysis. The analysis identified increased expression of four cell surface molecules in PC-3B1 cells that may be suitable as molecular imaging candidates to detect bone micro metastases.</p>","PeriodicalId":22947,"journal":{"name":"The open prostate cancer journal","volume":"2 ","pages":"59-66"},"PeriodicalIF":0.0,"publicationDate":"2009-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3212735/pdf/nihms164369.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30107580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 8

Structure‐Based Androgen Receptor Gene Mutation Database: A Tool to Link Molecular Location and Receptor Function 基于结构的雄激素受体基因突变数据库:连接分子定位和受体功能的工具

The open prostate cancer journal

Pub Date : 2002-03-05 DOI: 10.1046/J.1525-1411.2001.32004.X

L. Brive, D. Agus, K. R. Ely

Background: Mutant androgen receptors (ARs) that arise in prostate cancer cells may contribute directly to the development of advanced disease in some patients. Therefore, a structural understanding of the altered receptors will provide new information about the molecular triggers that lead to androgen-independent disease or metastatic spread. Methods: Recognizing that molecular localization is required to understand the effect of AR mutations on receptor function, a structural model of the ligand-binding domain of AR was used to locate a comprehensive set of mutations in this domain that occur in prostate cancer. Substitutions were grouped into those that are likely to affect (1) ligand binding, (2) dimerization, or (3) coactivator binding/transactivation. Results: The results were tabulated and were used to develop a novel structure-based database linking molecular location with clinical observations for each mutant receptor expressed in the prostate cancer cells. Categories in the database can be cross-referenced to retrieve, for each mutation, molecular details of the substitution, clinical stage of the disease, treatment history, and functional phenotype of the mutant receptor. Conclusions: This database will be a resource for the development of therapeutics targeted to the AR and for understanding the role of ARs in androgen independence.

背景:前列腺癌细胞中出现的雄激素受体(ARs)突变可能直接导致一些患者的晚期疾病发展。因此，对改变受体的结构理解将为导致雄激素非依赖型疾病或转移性扩散的分子触发提供新的信息。方法:认识到AR突变对受体功能的影响需要分子定位，我们使用AR配体结合结构域的结构模型来定位在前列腺癌中发生的该结构域的一组全面突变。取代被分为可能影响(1)配体结合，(2)二聚化，或(3)辅激活剂结合/转激活的取代。结果:结果被制成表格，并用于开发一个新的基于结构的数据库，将前列腺癌细胞中表达的每个突变受体的分子位置与临床观察联系起来。数据库中的分类可以交叉引用，以检索每个突变，替代的分子细节，疾病的临床阶段，治疗史和突变受体的功能表型。结论:该数据库将为开发针对AR的治疗方法和了解AR在雄激素依赖性中的作用提供资源。

{"title":"Structure‐Based Androgen Receptor Gene Mutation Database: A Tool to Link Molecular Location and Receptor Function","authors":"L. Brive, D. Agus, K. R. Ely","doi":"10.1046/J.1525-1411.2001.32004.X","DOIUrl":"https://doi.org/10.1046/J.1525-1411.2001.32004.X","url":null,"abstract":"Background: Mutant androgen receptors (ARs) that arise in prostate cancer cells may contribute directly to the development of advanced disease in some patients. Therefore, a structural understanding of the altered receptors will provide new information about the molecular triggers that lead to androgen-independent disease or metastatic spread. \u0000 \u0000 \u0000 \u0000Methods: Recognizing that molecular localization is required to understand the effect of AR mutations on receptor function, a structural model of the ligand-binding domain of AR was used to locate a comprehensive set of mutations in this domain that occur in prostate cancer. Substitutions were grouped into those that are likely to affect (1) ligand binding, (2) dimerization, or (3) coactivator binding/transactivation. \u0000 \u0000 \u0000 \u0000Results: The results were tabulated and were used to develop a novel structure-based database linking molecular location with clinical observations for each mutant receptor expressed in the prostate cancer cells. Categories in the database can be cross-referenced to retrieve, for each mutation, molecular details of the substitution, clinical stage of the disease, treatment history, and functional phenotype of the mutant receptor. \u0000 \u0000 \u0000 \u0000Conclusions: This database will be a resource for the development of therapeutics targeted to the AR and for understanding the role of ARs in androgen independence.","PeriodicalId":22947,"journal":{"name":"The open prostate cancer journal","volume":"49 1","pages":"76-91"},"PeriodicalIF":0.0,"publicationDate":"2002-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77601801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Lack of Effect of Aminoglutethimide and Hydrocortisone Added to High-Dose Bicalutamide for Androgen-Independent Prostate Cancer 氨甲硫胺和氢化可的松加入大剂量比卡鲁胺治疗雄激素非依赖型前列腺癌的疗效缺乏

The open prostate cancer journal

Pub Date : 2001-04-01 DOI: 10.1046/J.1525-1411.2001.32008.X

G. Bubley, S. Balk, R. Joyce, M. Taplin

Objectives: To determine whether hormones derived from the adrenal gland affected the progression of androgen-independent (AI) prostate cancer for patients already receiving treatment with high-dose bicalutamide. This was accomplished by using a sequential trial design in which medically or surgically castrated patients with AI prostate cancer whose cancers were progressing while receiving bicalutamide were treated with adrenolytic therapy in the form of aminoglutethimide (AM) and hydrocortisone (HC). Materials and Methods: Sixteen patients with AI prostate cancer were enrolled into this trial. All patients had metastatic disease in the bone, and two patients had additional metastases at other sites. Using prostate specific antigen (PSA) level as an indicator of disease activity, patients initially received bicalutamide therapy, then AM and HC were added to the regimen, and then bicalutamide therapy was discontinued, with each documented PSA level increase (see Figure 1). Figure 1. Clinical Trial Study Design: Patients were treated with sequential hormonal interventions according to the scheme depicted above. Download figure to PowerPoint Results: Four (25%) patients demonstrated PSA level reductions of at least 50% after the initiation of bicalutamide, 150 mg/day. No patient demonstrated a PSA or obvious clinical response to the addition of AM and HC to the regimen. This includes the four patients who were initially sensitive to bicalutamide. Therapy with AM and HC was associated with fatigue and skin rashes. These side effects persisted after the withdrawal of bicalutamide therapy and were therefore attributed to AM and HC therapy. Conclusions: Bicalutamide at high doses seems to effectively block the androgen receptor (AR) from the growth stimulation derived from adrenal hormones. Therefore, the inhibition of adrenal hormone production by AM is not a useful therapeutic maneuver in this setting and is associated with moderate side effects. The activation of the AR pathway in these patients may occur by a mechanism other than stimulation by the androgens derived from the testes or adrenal gland.

目的:确定肾上腺来源的激素是否影响已经接受大剂量比卡鲁胺治疗的雄激素非依赖性(AI)前列腺癌的进展。这是通过使用顺序试验设计来完成的，其中药物或手术阉割的AI前列腺癌患者在接受比卡鲁胺治疗时癌症进展，并以氨酰硫胺(AM)和氢化可的松(HC)的形式进行肾上腺素溶解治疗。材料与方法:入选16例AI前列腺癌患者。所有患者都有骨转移性疾病，两名患者在其他部位有额外的转移。以前列腺特异性抗原(PSA)水平作为疾病活动性的指标，患者最初接受比卡鲁胺治疗，然后在方案中加入AM和HC，然后停止比卡鲁胺治疗，每次记录的PSA水平升高(见图1)。临床试验研究设计:患者按照上述方案接受序贯激素干预治疗。结果:4例(25%)患者在开始使用比卡鲁胺150mg /天后，PSA水平降低了至少50%。没有患者表现出PSA或明显的临床反应，以增加AM和HC方案。这包括4名最初对比卡鲁胺敏感的患者。用AM和HC治疗与疲劳和皮疹相关。这些副作用在比卡鲁胺治疗停药后持续存在，因此归因于AM和HC治疗。结论:高剂量的比卡鲁胺似乎可以有效地阻断雄激素受体(AR)对肾上腺激素的生长刺激。因此，在这种情况下，AM抑制肾上腺激素的产生并不是一种有用的治疗方法，而且伴有中度副作用。在这些患者中，AR通路的激活可能是由睾丸或肾上腺来源的雄激素刺激以外的机制发生的。

{"title":"Lack of Effect of Aminoglutethimide and Hydrocortisone Added to High-Dose Bicalutamide for Androgen-Independent Prostate Cancer","authors":"G. Bubley, S. Balk, R. Joyce, M. Taplin","doi":"10.1046/J.1525-1411.2001.32008.X","DOIUrl":"https://doi.org/10.1046/J.1525-1411.2001.32008.X","url":null,"abstract":"Objectives: To determine whether hormones derived from the adrenal gland affected the progression of androgen-independent (AI) prostate cancer for patients already receiving treatment with high-dose bicalutamide. This was accomplished by using a sequential trial design in which medically or surgically castrated patients with AI prostate cancer whose cancers were progressing while receiving bicalutamide were treated with adrenolytic therapy in the form of aminoglutethimide (AM) and hydrocortisone (HC). \u0000 \u0000 \u0000 \u0000Materials and Methods: Sixteen patients with AI prostate cancer were enrolled into this trial. All patients had metastatic disease in the bone, and two patients had additional metastases at other sites. Using prostate specific antigen (PSA) level as an indicator of disease activity, patients initially received bicalutamide therapy, then AM and HC were added to the regimen, and then bicalutamide therapy was discontinued, with each documented PSA level increase (see Figure 1). \u0000 \u0000 \u0000 \u0000 \u0000Figure 1. Clinical Trial Study Design: Patients were treated with sequential hormonal interventions according to the scheme depicted above. \u0000 \u0000Download figure to PowerPoint \u0000 \u0000 \u0000 \u0000 \u0000Results: Four (25%) patients demonstrated PSA level reductions of at least 50% after the initiation of bicalutamide, 150 mg/day. No patient demonstrated a PSA or obvious clinical response to the addition of AM and HC to the regimen. This includes the four patients who were initially sensitive to bicalutamide. Therapy with AM and HC was associated with fatigue and skin rashes. These side effects persisted after the withdrawal of bicalutamide therapy and were therefore attributed to AM and HC therapy. \u0000 \u0000 \u0000 \u0000Conclusions: Bicalutamide at high doses seems to effectively block the androgen receptor (AR) from the growth stimulation derived from adrenal hormones. Therefore, the inhibition of adrenal hormone production by AM is not a useful therapeutic maneuver in this setting and is associated with moderate side effects. The activation of the AR pathway in these patients may occur by a mechanism other than stimulation by the androgens derived from the testes or adrenal gland.","PeriodicalId":22947,"journal":{"name":"The open prostate cancer journal","volume":"64 1","pages":"98-104"},"PeriodicalIF":0.0,"publicationDate":"2001-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86131595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

HER‐Kinase‐Directed Therapy of Prostate Cancer HER激酶定向治疗前列腺癌

The open prostate cancer journal

Pub Date : 2001-04-01 DOI: 10.1046/J.1525-1411.2001.32006.X

D. Solit, D. Agus

引用次数: 3

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

The open prostate cancer journal

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀